253 related articles for article (PubMed ID: 25125335)
1. Proteasome inhibitors with photocontrolled activity.
Hansen MJ; Velema WA; de Bruin G; Overkleeft HS; Szymanski W; Feringa BL
Chembiochem; 2014 Sep; 15(14):2053-7. PubMed ID: 25125335
[TBL] [Abstract][Full Text] [Related]
2. Azobenzene-containing photoswitchable proteasome inhibitors with selective activity and cellular toxicity.
Blanco B; Palasis KA; Adwal A; Callen DF; Abell AD
Bioorg Med Chem; 2017 Oct; 25(19):5050-5054. PubMed ID: 28642029
[TBL] [Abstract][Full Text] [Related]
3. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from β-amino acid as proteasome inhibitors.
Zhang J; Cao J; Xu L; Zhou Y; Liu T; Li J; Hu Y
Bioorg Med Chem; 2014 Jun; 22(11):2955-65. PubMed ID: 24767818
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and pharmacology of proteasome inhibitors.
Rentsch A; Landsberg D; Brodmann T; Bülow L; Girbig AK; Kalesse M
Angew Chem Int Ed Engl; 2013 May; 52(21):5450-88. PubMed ID: 23526565
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, and Biological Activity of Isosyringolin A.
Kitahata S; Chiba T; Yoshida T; Ri M; Iida S; Matsuda A; Ichikawa S
Org Lett; 2016 May; 18(9):2312-5. PubMed ID: 27123978
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.
Niroula D; Hallada LP; Le Chapelain C; Ganegamage SK; Dotson D; Rogelj S; Groll M; Tello-Aburto R
Eur J Med Chem; 2018 Sep; 157():962-977. PubMed ID: 30165344
[TBL] [Abstract][Full Text] [Related]
8. Activity enhancement of the synthetic syrbactin proteasome inhibitor hybrid and biological evaluation in tumor cells.
Archer CR; Groll M; Stein ML; Schellenberg B; Clerc J; Kaiser M; Kondratyuk TP; Pezzuto JM; Dudler R; Bachmann AS
Biochemistry; 2012 Aug; 51(34):6880-8. PubMed ID: 22870914
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, bioactivity, docking and molecular dynamics studies of furan-based peptides as 20S proteasome inhibitors.
Sun Q; Xu B; Niu Y; Xu F; Liang L; Wang C; Yu J; Yan G; Wang W; Jin H; Xu P
ChemMedChem; 2015 Mar; 10(3):498-510. PubMed ID: 25641789
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design of human immuno- and constitutive proteasomes inhibitors.
Richy N; Sarraf D; Maréchal X; Janmamode N; Le Guével R; Genin E; Reboud-Ravaux M; Vidal J
Eur J Med Chem; 2018 Feb; 145():570-587. PubMed ID: 29339252
[TBL] [Abstract][Full Text] [Related]
11. Pharmacophore modeling technique applied for the discovery of proteasome inhibitors.
Pautasso C; Troia R; Genuardi M; Palumbo A
Expert Opin Drug Discov; 2014 Aug; 9(8):931-43. PubMed ID: 24877566
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors.
Yu J; Xu L; Hong D; Zhang X; Liu J; Li D; Li J; Zhou Y; Liu T
Eur J Med Chem; 2019 Jan; 161():543-558. PubMed ID: 30391816
[TBL] [Abstract][Full Text] [Related]
13. Studies of C-terminal naphthoquinone dipeptides as 20S proteasome inhibitors.
Scotti A; Trapella C; Ferretti V; Gallerani E; Gavioli R; Marastoni M
J Enzyme Inhib Med Chem; 2016; 31(3):456-63. PubMed ID: 25942361
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of novel spin labeled 18β-glycyrrhetinic acid derivatives.
Liu Y; Qian K; Wang CY; Chen CH; Yang X; Lee KH
Bioorg Med Chem Lett; 2012 Dec; 22(24):7530-3. PubMed ID: 23122524
[TBL] [Abstract][Full Text] [Related]
15. New 26S proteasome inhibitors with high selectivity for chymotrypsin-like activity and p53-dependent cytotoxicity.
Neilsen PM; Pehere AD; Pishas KI; Callen DF; Abell AD
ACS Chem Biol; 2013 Feb; 8(2):353-9. PubMed ID: 23190346
[TBL] [Abstract][Full Text] [Related]
16. Exploring the Binding Affinity of Novel Syringic Acid Analogues and Critical Determinants of Selectivity as Potent Proteasome Inhibitors.
Cheemanapalli S; Anuradha CM; Madhusudhana P; Mahesh M; Raghavendra PB; Kumar CS
Anticancer Agents Med Chem; 2016; 16(11):1496-1510. PubMed ID: 27173965
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of curcumin derivatives modified with α-amino boronic acid as proteasome inhibitors.
Zhang W; Bai H; Han L; Zhang H; Xu B; Cui J; Wang X; Ge Z; Li R
Bioorg Med Chem Lett; 2018 Aug; 28(14):2459-2464. PubMed ID: 29886021
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the Proteasome β2 Site Sensitizes Triple-Negative Breast Cancer Cells to β5 Inhibitors and Suppresses Nrf1 Activation.
Weyburne ES; Wilkins OM; Sha Z; Williams DA; Pletnev AA; de Bruin G; Overkleeft HS; Goldberg AL; Cole MD; Kisselev AF
Cell Chem Biol; 2017 Feb; 24(2):218-230. PubMed ID: 28132893
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes.
de Bruin G; Huber EM; Xin BT; van Rooden EJ; Al-Ayed K; Kim KB; Kisselev AF; Driessen C; van der Stelt M; van der Marel GA; Groll M; Overkleeft HS
J Med Chem; 2014 Jul; 57(14):6197-209. PubMed ID: 25006746
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of tripeptidyl furylketones as selective inhibitors against the β5 subunit of human 20S proteasome.
Sun Q; Zhou T; Xi D; Li X; Lü Z; Xu F; Wang C; Niu Y; Xu P
Eur J Med Chem; 2020 Apr; 192():112160. PubMed ID: 32146375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
